Ginkgo Bioworks (DNA)
(Delayed Data from NYSE)
$0.93 USD
-0.05 (-5.48%)
Updated May 7, 2024 04:00 PM ET
After-Market: $0.94 +0.01 (0.64%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Ginkgo Bioworks Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 944 | 1,316 | 1,550 | 0 | 0 |
Receivables | 18 | 82 | 136 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 4 | 3 | 0 | 0 |
Other Current Assets | 40 | 47 | 34 | 0 | 0 |
Total Current Assets | 1,002 | 1,450 | 1,723 | 0 | 0 |
Net Property & Equipment | 188 | 315 | 146 | 0 | 0 |
Investments & Advances | 79 | 114 | 115 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 1 | 0 |
Intangibles | 132 | 171 | 43 | 0 | 0 |
Deposits & Other Assets | 58 | 89 | 44 | 0 | 0 |
Total Assets | 1,665 | 2,539 | 2,071 | 1 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 8 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 110 | 115 | 93 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 44 | 48 | 33 | 0 | 0 |
Total Current Liabilities | 164 | 173 | 135 | 1 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 158 | 175 | 175 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 22 | 0 | 0 |
Other Non-Current Liabilities | 24 | 42 | 172 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 568 | 803 | 504 | 1 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 6,386 | 6,136 | 3,805 | 0 | 0 |
Retained Earnings | -5,291 | -4,398 | -2,298 | 0 | 0 |
Other Equity | 1 | -3 | 60 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,097 | 1,736 | 1,567 | 0 | 0 |
Total Liabilities & Shareholder's Equity | 1,665 | 2,539 | 2,071 | 1 | 0 |
Total Common Equity | 1,097 | 1,736 | 1,567 | 0 | 0 |
Shares Outstanding | 2,001.30 | 1,939.90 | 1,690.90 | NA | NA |
Book Value Per Share | 0.55 | 0.90 | 0.93 | 0.00 | 0.00 |
Fiscal Year End for Ginkgo Bioworks Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 944 | 1,049 | 1,106 | 1,206 |
Receivables | NA | 18 | 63 | 69 | 85 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 3 |
Other Current Assets | NA | 40 | 29 | 48 | 34 |
Total Current Assets | NA | 1,002 | 1,142 | 1,223 | 1,327 |
Net Property & Equipment | NA | 188 | 202 | 294 | 314 |
Investments & Advances | NA | 79 | 86 | 121 | 123 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 132 | 158 | 164 | 167 |
Deposits & Other Assets | NA | 58 | 97 | 98 | 97 |
Total Assets | NA | 1,665 | 2,026 | 2,292 | 2,417 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 11 | 14 | 22 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 110 | 115 | 110 | 123 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 44 | 43 | 39 | 48 |
Total Current Liabilities | NA | 164 | 168 | 163 | 192 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 158 | 170 | 180 | 175 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 32 | 34 | 39 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 568 | 774 | 788 | 810 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 6,386 | 6,334 | 6,281 | 6,212 |
Retained Earnings | NA | -5,291 | -5,079 | -4,776 | -4,603 |
Other Equity | NA | 1 | -3 | -1 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 1,097 | 1,253 | 1,504 | 1,608 |
Total Liabilities & Shareholder's Equity | NA | 1,665 | 2,026 | 2,292 | 2,417 |
Total Common Equity | 0 | 1,097 | 1,253 | 1,504 | 1,608 |
Shares Outstanding | 2,152.40 | 2,001.30 | 1,972.70 | 2,085.50 | 2,072.50 |
Book Value Per Share | 0.00 | 0.55 | 0.64 | 0.72 | 0.78 |